Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals successfully raised $625 million through convertible notes and common stock offerings. This substantial capital infusion will fund pipeline development, operations, and potential product launches. The offerings include 0.00% convertible senior notes due 2032 and common stock, with underwriters having options to purchase additional securities. The company also utilized capped call transactions to mitigate potential dilution from note conversions. Proceeds will support R&D, clinical trials, and general corporate purposes.